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older (adults). The mean length of stay was 10 days for
all cases with a mean cost per stay estimated at €3259.
Costs increased to €3816 for those <1 year based on a
mean LOS of 11.5 days. On average, those in the 6–15
year age group had the lowest LOS and cost per stay (6.5
days; €2157) and adults had the highest (11.9 days;
€3965). CONCLUSIONS: While most pertussis cases can
be managed in an outpatient setting, the need for hospi-
talization does occur across all age groups in Germany.
When hospitalization is required, a considerable expense
is incurred. Thus, the cost of hospitalization should be
factored into any economic analysis or decision-making
process examining the beneﬁts of vaccination to prevent
the occurrence of this infectious disease.
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Introduction: Inﬂuenza (IZ) is a highly contagious acute
respiratory disease with self-limiting duration, represent-
ing serious health risks for the elderly and those with
chronic diseases. Vaccination is effective, but the most
vulnerable population remains at risk of IZ. New, drugs
entered the market, able to reduce IZ symptoms by 1.5
°V2 days when taken within 48h of symptom onset. We
investigated the WTP for these drugs under the constraint
of information and prescription. METHOD: Population:
Health professionals, patients with chronic diseases 
and young healthy adults. Willingness to pay (WTP) was
asked through closed ended questions, using a payment
card system with increasing and decreasing bidding
ranges. Questionnaires contained 3 scenarios including 2
levels of information and were randomly allocated. 1rst
scenario informed about IZ and asked WTP for no IZ
risk, the 2nd WTP for the drugs, under time and ofﬁce
visit constraint, 3rd scenario addressed WTP for drugs 
if obtainable over the counter (OTC). RESULTS: We
obtained 1594 answers, 59% female 41% male, evenly
distributed for information, starting point and insurance.
For scenario 2, 36% were unwilling to give anything,
while only 22% answered nothing with the option of
having the drug OTC, 41% were even willing to give
more than 80CHF. WTP decreased signiﬁcantly with age.
Insurance had no inﬂuence on WTP and health profes-
sionals had a signiﬁcantly lower WTP than others.
Bidding ranges had no inﬂuence, neither did the level of
information. Participants who had been vaccinated
against inﬂuenza last year were willing to give more.
CONCLUSION: We completed successfully the ﬁrst large
randomized WTP study in Health Care. Respondents
valued independent decision-making, favouring the 3rd
scenario Preferences of participants were much lower
than the drugs market price (CHF 80). Further large WTP
studies need to be undertaken to conﬁrm the WTP
approach in Health Care.
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OBJECTIVES: The aim of study to assess the costs and
cost distribution of pulmonary tuberculosis in Ukraine
from the perspective of public health care in Ukraine.
METHODS: The direct medical costs, doctor consulta-
tions, laboratory and diagnostic tests, and hospitaliza-
tions were identiﬁed and calculated. Indirect costs due to
lost productivity were also included. RESULTS: The data
collected from 8867 patients in West regional pulmonary
centre (sity Lviv) for 2000–2002 were analysed. The
average cost per pulmonary tuberculosis patient per year
was calculated at 835 UAH (€Euro = 6.1 UAH). The dis-
ribution of total costs is as follows: pharmacological
treatment (42.5%), laborabory and diagnostic tests
(8,2%), doctors’ consultation (10.5%), hospitalization
(26.4%) and productivity loss (12.4%). Indirect costs of
pulmonary tuberculosis in Ukraine were much lower,
because a social structure of patients on Ukraine has
allowed to detect, that persons who were come back from
places of an inference—10–20%, the alcogolics—
20–50%, the immigrants—5–10%, persons not having 
of normal housing conditions and living in hostels—
10–15%. Theoretically the total burden of pulmonary
tuberculosis on society per year amounts 28.1 million
UAH (€4.6 million). CONCLUSIONS: Pulmonary tuber-
culosis represents an important economic burden for the
Ukrainian population. An optimal allocation of expendi-
ture for pharmacological treatment and hospitalization
may contribute to a signiﬁcant reduction of the total cost
of pulmonary tuberculosis in Ukraine.
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OBJECTIVES: Although efﬁcacy of alternative antibiotic
dosing regimes may be the same, compliance may vary
thus affecting treatment effectiveness. The objective of
this study was to assess the efﬁciency of once-daily 
clarithromycin (CL OD) versus conventional twice-daily
generic clarithromycin (CL BD), in patients with tonsil-
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lopharingytis, acute exacerbation of chronic bronchitis
(AECB) and community acquired pneumonia (CAP).
METHODS: A decision-tree model was build to calculate
the cost-effectiveness of the comparators in 2 cohorts of
1000 patients with each condition with a time horizon of
2 months. The study was conducted from the perspective
of the Spanish NHS but an alternative scenario included
the productivity losses. Efﬁcacy rates were retrieved from
published randomized controlled clinical trials. Compli-
ance rates were retrieved from a published clinical study
that evaluated patient compliance to antibiotic therapy
with OD, BD and three times daily dosing. Health care
resource use in each condition was retrieved from a 
panel of 9 experts. The unit costs of resources were
obtained from national databases (€2003). The results 
of the study were expressed in terms of incremental 
cost-effectiveness ratio (ICER) per patient experiencing
improvement or cure. RESULTS: The incremental effec-
tiveness of the OD regime vs. BD regime is 10%, 14%
and 16%, in tonsillopharingytis, AEBC and CAP, respec-
tively. The ICER was €13 in tonsillopharingytis. In AEBC
and CAP, CL OD is the dominant treatment strategy,
offering higher effectiveness at lower costs. The scenario
including productivity losses shows that the treatment
with CL OD becomes less costly than CL BD in the three
conditions ranging from -7 euros (tonsillopharingytis) 
to -€158 (CAP) per patient treated. CONCLUSIONS:
Higher compliance rates with CL OD vs. CL BD increase
treatment effectiveness and improve the efﬁciency of the
OD antibiotic treatment. Considering productivity losses,
CL OD is a cost-saving option in all conditions under
analysis.
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OBJECTIVES: Worldwide, a large burden of invasive
bacterial infections in infants is caused by meningococcal
B, C and pneumococcal infections. In this presentation,
the potential impact of a neonatal program with a newly
developed combination vaccine in the Netherlands is
analysed. METHODS: A decision analysis framework
was developed using epidemiological and health care
resource use data from 1996–2001. This model is used to
estimate costs, beneﬁts, and health gains associated with
vaccinating all newborns. In the resulting cost-
effectiveness analysis, the societal perspective is taken.
RESULTS: Annually, on average 663 cases of invasive
pneumococcal and meningococcal B and C infection
occur in infants aged 0 to 10 years. Introduction of the
combination vaccine would prevent 233 cases of menin-
gitis and 115 cases of bacteremia per year. Additionally,
3020 cases of pneumococcal pneumonia and 38,870 cases
of otitis media would be prevented. Vaccination saves 34
lives per year and prevents 69 cases of severe sequelae.
This translates into 845 life years gained, or 999 quality
adjusted life years gained. Next to these health gains, 
vaccination will prevent €18,310,882 of the direct and
indirect medical costs due to meningococcal and 
pneumococcal infections in the Netherlands. Base case
cost-effectiveness (vaccine price €40) is €17,951 per
QALY. The model is most sensitive to changes in inci-
dence, vaccine price, and duration of protective efﬁcacy.
CONCLUSIONS: The introduction of this vaccine for
infants leadS to large reductions in morbidity and mor-
tality, and is a potentially cost-effective preventive 
intervention.
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OBJECTIVE: To estimate the costs and effects of differ-
ent treatment strategies with intrapartum antibiotic pro-
phylaxis to prevent early-onset group B streptococcal
disease in the Netherlands. The treatment strategies
include a risk-based strategy, a screening based strategy,
a combined screening/risk based strategy, and the current
Dutch guideline. METHODS: A decision analysis model
was used to compare the costs and effects of different
treatment strategies with no treatment for a hypothetical
cohort of 200,000 neonates. Baseline estimates were
derived from literature and a survey among parents of
GBS children. The analysis was performed from a soci-
etal perspective, and costs and effects were discounted at
a percentage of 3%. RESULTS: The introduction of 
a combined screening/risk-based strategy with universal
screening in pregnancy providing intrapartum prophy-
laxis for women with a risk factor or for unscreened
women with pre-term labor would prevent 362 of the 600
cases with early-onset GBS for €9200 per QALY gained.
The risk-based strategy is also an efﬁcient strategy pre-
venting 379 cases of onset GBS and a cost-effectiveness
ratio of €10,200 per QALY gained. The other strategies
resulted in lower effects for higher costs. Introducing 
the PCR test does not lead to more favorable cost-
effectiveness ratios. CONCLUSIONS: In the Dutch
